Terms: = Prostate cancer AND RPL22, EAP, 6146
11 results:
1. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O; Vogelzang NJ; Sweeney C; Fernandez DC; Almeida F; Iagaru A; Brown A; Smith MR; Agrawal M; Dicker AP; Garcia JA; Lutzky J; Wong YN; Petrenciuc O; Gratt J; Shore ND; Morris MJ;
Oncologist; 2018 Feb; 23(2):193-202. PubMed ID: 29183960
[TBL] [Abstract] [Full Text] [Related]
2. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.
Parente P; Ng S; Parnis F; Guminski A; Gurney H
Asia Pac J Clin Oncol; 2017 Dec; 13(6):391-399. PubMed ID: 28488360
[TBL] [Abstract] [Full Text] [Related]
3. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in prostate cancer.
Di Lorenzo G; Bracarda S; Gasparro D; Gernone A; Messina C; Zagonel V; Puglia L; Bosso D; Dondi D; Sonpavde G; Lucarelli G; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Jan; 95(2):e2299. PubMed ID: 26765406
[TBL] [Abstract] [Full Text] [Related]
4. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz M; Berry W; Mukherjee SD; Winquist E; Haas NB; Foley MA; Dmuchowski C; Perabo F; Hirmand M; Hasabou N; Rathkopf D;
Prostate; 2015 Jun; 75(8):836-44. PubMed ID: 25683285
[TBL] [Abstract] [Full Text] [Related]
5. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (eap) (NCT01254279).
Bahl A; Masson S; Malik Z; Birtle AJ; Sundar S; Jones RJ; James ND; Mason MD; Kumar S; Bottomley D; Lydon A; Chowdhury S; Wylie J; de Bono JS
BJU Int; 2015 Dec; 116(6):880-7. PubMed ID: 25639506
[TBL] [Abstract] [Full Text] [Related]
6. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract] [Full Text] [Related]
7. Construction of a star-shaped copolymer as a vector for FGF receptor-mediated gene delivery in vitro and in vivo.
Li D; Ping Y; Xu F; Yu H; Pan H; Huang H; Wang Q; Tang G; Li J
Biomacromolecules; 2010 Sep; 11(9):2221-9. PubMed ID: 20704346
[TBL] [Abstract] [Full Text] [Related]
8. Ultrahigh sensitivity made simple: nanoplasmonic label-free biosensing with an extremely low limit-of-detection for bacterial and cancer diagnostics.
Chen S; Svedendahl M; Käll M; Gunnarsson L; Dmitriev A
Nanotechnology; 2009 Oct; 20(43):434015. PubMed ID: 19801769
[TBL] [Abstract] [Full Text] [Related]
9. Autoimmune prostatitis: state of the art.
Motrich RD; Maccioni M; Riera CM; Rivero VE
Scand J Immunol; 2007; 66(2-3):217-27. PubMed ID: 17635799
[TBL] [Abstract] [Full Text] [Related]
10. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
Naito S; Ueda T; Kotoh S; Kumazawa J; Itoh K; Sagiyama K; Omoto T; Andoh S; Hasegawa Y; Fujisawa Y
Cancer Chemother Pharmacol; 1995; 35(3):225-9. PubMed ID: 7805181
[TBL] [Abstract] [Full Text] [Related]
11. Chemotherapy for endocrine-therapy-refractory prostate cancer.
Akimoto S; Ohki T; Akakura K; Masai M; Shimazaki J
Cancer Chemother Pharmacol; 1994; 35 Suppl():S18-22. PubMed ID: 7527733
[TBL] [Abstract] [Full Text] [Related]
